Document is current

Any future updates will be listed below

1217 Efficacy and additional mechanism of action of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, in preclinical models of non-muscle invasive bladder cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.1217

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark